Robert Tatum, PA-C

NPI: 1801841325
Total Payments
$19,747
2024 Payments
$6,790
Companies
4
Transactions
52
Medicare Patients
145
Medicare Billing
$11,491

Payment Breakdown by Category

Other$14,160 (71.7%)
Travel$2,287 (11.6%)
Consulting$1,900 (9.6%)
Food & Beverage$1,400 (7.1%)

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for serving as faculty or as a speaker for a medical education program $8,200 9 41.5%
Honoraria $3,580 8 18.1%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,380 1 12.1%
Travel and Lodging $2,287 12 11.6%
Consulting Fee $1,900 2 9.6%
Food and Beverage $1,400 20 7.1%

Top Paying Companies

Company Total Records Latest Year
Intercept Pharmaceuticals, Inc. $15,544 35 $0 (2024)
Madrigal Pharmaceuticals $3,981 15 $0 (2024)
Gilead Sciences, Inc. $121.84 1 $0 (2024)
Novo Nordisk Inc $100.53 1 $0 (2022)

Payment History by Year

Year Amount Transactions Top Company
2024 $6,790 20 Madrigal Pharmaceuticals ($3,981)
2023 $7,427 12 INTERCEPT PHARMACEUTICALS, INC. ($7,427)
2022 $4,200 13 INTERCEPT PHARMACEUTICALS, INC. ($4,099)
2021 $1,330 7 Intercept Pharmaceuticals, Inc. ($1,330)

All Payment Transactions

52 individual payment records from CMS Open Payments — Page 1 of 3

Date Company Product Nature Form Amount Type
12/19/2024 Madrigal Pharmaceuticals RESMETIROM (Drug) Food and Beverage In-kind items and services $10.53 General
Category: LIVER DISEASE
11/17/2024 Madrigal Pharmaceuticals RESMETIROM (Drug) Food and Beverage In-kind items and services $70.04 General
Category: LIVER DISEASE
10/31/2024 Madrigal Pharmaceuticals RESMETIROM (Drug) Food and Beverage In-kind items and services $12.26 General
Category: LIVER DISEASE
10/31/2024 Madrigal Pharmaceuticals RESMETIROM (Drug) Food and Beverage In-kind items and services $6.73 General
Category: LIVER DISEASE
09/27/2024 Madrigal Pharmaceuticals REZDIFFRA (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,380.00 General
Category: LIVER DISEASE
09/27/2024 Madrigal Pharmaceuticals REZDIFFRA (Drug) Travel and Lodging In-kind items and services $254.00 General
Category: LIVER DISEASE
09/27/2024 Madrigal Pharmaceuticals REZDIFFRA (Drug) Travel and Lodging In-kind items and services $226.86 General
Category: LIVER DISEASE
09/27/2024 Madrigal Pharmaceuticals REZDIFFRA (Drug) Travel and Lodging In-kind items and services $218.48 General
Category: LIVER DISEASE
09/27/2024 Madrigal Pharmaceuticals REZDIFFRA (Drug) Travel and Lodging In-kind items and services $193.00 General
Category: LIVER DISEASE
09/27/2024 Madrigal Pharmaceuticals REZDIFFRA (Drug) Food and Beverage In-kind items and services $186.86 General
Category: LIVER DISEASE
09/27/2024 Madrigal Pharmaceuticals REZDIFFRA (Drug) Travel and Lodging In-kind items and services $103.48 General
Category: LIVER DISEASE
09/27/2024 Madrigal Pharmaceuticals REZDIFFRA (Drug) Food and Beverage In-kind items and services $94.62 General
Category: LIVER DISEASE
09/27/2024 Madrigal Pharmaceuticals REZDIFFRA (Drug) Food and Beverage In-kind items and services $80.91 General
Category: LIVER DISEASE
09/27/2024 Madrigal Pharmaceuticals REZDIFFRA (Drug) Food and Beverage In-kind items and services $77.39 General
Category: LIVER DISEASE
09/27/2024 Madrigal Pharmaceuticals REZDIFFRA (Drug) Travel and Lodging Cash or cash equivalent $65.95 General
Category: LIVER DISEASE
09/04/2024 Gilead Sciences, Inc. Livdelzi (Drug) Food and Beverage In-kind items and services $121.84 General
Category: INFLAM
06/18/2024 Intercept Pharmaceuticals, Inc. OCALIVA (Drug) Compensation for serving as faculty or as a speaker for a medical education program Cash or cash equivalent $1,520.00 General
Category: Hepatology / Gastroenterology
06/18/2024 Intercept Pharmaceuticals, Inc. OCALIVA (Drug) Food and Beverage In-kind items and services $122.20 General
Category: Hepatology / Gastroenterology
04/25/2024 Intercept Pharmaceuticals, Inc. OCALIVA (Drug) Compensation for serving as faculty or as a speaker for a medical education program Cash or cash equivalent $665.00 General
Category: Hepatology / Gastroenterology
03/25/2024 Intercept Pharmaceuticals, Inc. OCALIVA (Drug) Honoraria Cash or cash equivalent $380.00 General
Category: Hepatology / Gastroenterology
11/27/2023 INTERCEPT PHARMACEUTICALS, INC. OCALIVA (Drug) Travel and Lodging Cash or cash equivalent $528.82 General
Category: Hepatology / Gastroenterology
11/17/2023 INTERCEPT PHARMACEUTICALS, INC. OCALIVA (Drug) Consulting Fee Cash or cash equivalent $1,520.00 General
Category: Hepatology / Gastroenterology
11/09/2023 INTERCEPT PHARMACEUTICALS, INC. OCALIVA (Drug) Food and Beverage In-kind items and services $111.31 General
Category: Hepatology / Gastroenterology
11/09/2023 INTERCEPT PHARMACEUTICALS, INC. OCALIVA (Drug) Food and Beverage In-kind items and services $107.01 General
Category: Hepatology / Gastroenterology
08/15/2023 INTERCEPT PHARMACEUTICALS, INC. OCALIVA (Drug) Compensation for serving as faculty or as a speaker for a medical education program Cash or cash equivalent $1,140.00 General
Category: Hepatology / Gastroenterology

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 1 39 41 $10,414 $3,044
2022 1 30 34 $8,636 $2,393
2021 1 41 44 $11,176 $3,326
2020 2 35 40 $11,940 $2,727
Total Patients
145
Total Services
159
Medicare Billing
$11,491
Procedure Codes
5

All Medicare Procedures & Services

5 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 39 41 $10,414 $3,044 29.2%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 30 34 $8,636 $2,393 27.7%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 41 44 $11,176 $3,326 29.8%
99215 Established patient office or other outpatient, visit typically 40 minutes Office 2020 17 20 $6,860 $1,487 21.7%
99214 Established patient office or other outpatient, visit typically 25 minutes Office 2020 18 20 $5,080 $1,240 24.4%

About Robert Tatum, PA-C

Robert Tatum, PA-C is a Physician Assistant healthcare provider based in Louisville, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801841325.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Robert Tatum, PA-C has received a total of $19,747 in payments from pharmaceutical and medical device companies, with $6,790 received in 2024. These payments were reported across 52 transactions from 4 companies. The most common payment nature is "Compensation for serving as faculty or as a speaker for a medical education program" ($8,200).

As a Medicare-enrolled provider, Tatum has provided services to 145 Medicare beneficiaries, totaling 159 services with total Medicare billing of $11,491. Data is available for 4 years (2020–2023), covering 5 distinct procedure/service records.

Practice Information

  • Specialty Physician Assistant
  • Location Louisville, KY
  • Active Since 05/23/2006
  • Last Updated 07/08/2007
  • Taxonomy Code 363A00000X
  • Entity Type Individual
  • NPI Number 1801841325

Products in Payments

  • OCALIVA (Drug) $15,544
  • REZDIFFRA (Drug) $3,882
  • Livdelzi (Drug) $121.84
  • RESMETIROM (Drug) $99.56

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Physician Assistant Doctors in Louisville